{
    "nct_id": "NCT05417789",
    "official_title": "A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour",
    "inclusion_criteria": "* Age >12 years\n* Biopsy-confirmed (standard of care diagnosis history) local or diffuse TGCT where surgical resection would be associated with predicted worsening functional limitations through surgical joint damage, and/or subject has an anticipated high risk of early recurrence as determined by a multidisciplinary tumour board or equivalent, or any other morbidity associated with the surgery, and/or surgical treatment is not expected to improve the clinical outcomes of the subject.\n* Measurable disease: longest diameter â‰¥20 mm.\n* Adequate organ and bone marrow function\n* If a woman of childbearing potential (WOCBP), must have a negative pregnancy test prior to starting treatment and agree to use a highly effective method of contraception\n* Participants must have given written consent\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* If a female, the subject is pregnant or breast feeding.\n* Medical conditions, including auto-immune, requiring systemic immunosuppression. Any systemic treatment for these conditions (eg, glucocorticoids) is not allowed within 4 weeks of Screening and during the study.\n* Known metastatic TGCT or other active cancer that requires concurrent or planned treatment\n* Received systemic therapy for TGCT (investigational or approved) targeting CSF-1 or CSF-1R or any multi-tyrosine kinase inhibitor (eg nilotinib and imatinib) within 3 months prior to screening\n* Any surgery, chemotherapy or radiotherapy within 3 months of screening\n* Unresolved clinically significant toxicity from a previous treatment or any history of serious liver toxicity.\n* Current or chronic history of liver disease.\n* Inadequate renal and liver function\n* Systemic antiretroviral therapy within 3 months of baseline\n* Within 6 months of baseline has experienced: clinically significant myocardial infarction, severe/unstable angina pectoris, congestive heart failure New York Heart Association (NYHA) Class III or IV, or pulmonary disease (NYHA Criteria 1994) including severe thromboembolic event; incompletely healed clinically significant wounds, including bone fractures; pathological fracture or significant hypercalcaemia.",
    "miscellaneous_criteria": ""
}